UPDATED May 08, 2024
Companies which may present a buying opportunity after a dip in share price.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ACI | ₹629.50 | -3.5% | 15.2% | ₹77.7b | ₹743.00 | PE19.5x | E29.0% | 0.3% | Materials | ||
301358 | CN¥37.17 | 6.1% | -11.2% | CN¥28.1b | n/a | PE19.3x | E30.3% | 1.1% | Capital Goods | ||
CAI | AU$0.13 | 0% | -29.7% | AU$99.0m | n/a | PB0.7x | E110.6% | n/a | Materials | ||
HHR | AU$0.007 | 0% | -77.4% | AU$19.7m | n/a | PE6.7x | E86.3% | n/a | Energy | ||
301325 | CN¥61.41 | -0.3% | n/a | CN¥7.4b | CN¥83.82 | PE22.2x | E24.9% | n/a | Capital Goods | ||
A036200 | ₩10,460.00 | -5.2% | 42.5% | ₩312.6b | ₩13,500.00 | PE17.1x | E38.6% | 0.8% | Semiconductors | ||
RCEL | US$8.96 | 3.6% | -44.1% | US$241.7m | US$25.90 | PS4.6x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
NEWBRY | kr3.06 | -10.3% | -45.4% | kr74.2m | kr8.00 | PS3.3x | E112.9% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$5.16 | 12.2% | 18.1% | US$216.6m | US$19.00 | PS7.8x | E68.0% | n/a | Pharmaceuticals & Biotech | ||
SEAPT | kr4.56 | -2.1% | -63.9% | kr1.6b | kr11.57 | PB0.9x | E54.2% | n/a | Energy | ||
300820 | CN¥46.87 | -6.6% | -34.5% | CN¥10.3b | CN¥70.67 | PE22.6x | E23.9% | 0.9% | Capital Goods | ||
KCB | KSh30.05 | 0.3% | 2.0% | KSh96.6b | KSh48.65 | PB0.4x | E26.0% | 0% | Banks | ||
300442 | CN¥29.68 | -5.5% | -4.7% | CN¥51.1b | CN¥36.36 | PE26.8x | E28.7% | 1.7% | Software | ||
FXPO | UK£0.50 | 0.5% | -54.0% | UK£293.9m | UK£1.41 | PB0.3x | E116.3% | 0% | Materials | ||
A101390 | ₩7,000.00 | -10.5% | -36.9% | ₩63.1b | n/a | PB2.8x | E100.8% | n/a | Tech | ||
DIGN | kr1.62 | 1.6% | -61.1% | kr114.2m | kr8.60 | PS1.3x | E139.0% | n/a | Healthcare | ||
CLBIO | kr10.05 | -4.7% | -39.5% | kr216.0m | kr29.00 | PS7x | E114.8% | n/a | Pharmaceuticals & Biotech | ||
ACR | AU$0.064 | 1.6% | 33.3% | AU$18.6m | n/a | PS1.6x | E115.3% | 0% | Pharmaceuticals & Biotech | ||
OX2 | kr41.54 | 3.5% | -40.7% | kr11.3b | kr70.75 | PE12.8x | E29.9% | n/a | Capital Goods | ||
CABP | UK£1.36 | 3.3% | n/a | UK£345.6m | UK£1.78 | PE15.1x | E34.6% | n/a | Diversified Financials | ||
631 | HK$6.46 | 17.2% | -39.5% | HK$20.6b | HK$10.52 | PE9.9x | E21.2% | 2.9% | Capital Goods | ||
FLNC | US$20.38 | 12.3% | 1.8% | US$3.7b | US$30.38 | PS1.1x | E65.2% | n/a | Capital Goods | ||
XBRANE | kr0.19 | -12.1% | -99.8% | kr291.2m | n/a | PS1.2x | E93.7% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$9.31 | 45.5% | 123.3% | US$2.2b | US$13.83 | PS13.7x | E60.7% | n/a | Pharmaceuticals & Biotech |